The International Association for the Study of Pain (IASP) de® nes that`pain is an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage' 1 . This represents an acknowledgement from the international medical community of the complexity of pain as a phenomenon, the possible discrepancy between tissue damage, perception and magnitude of pain and the possible impact on the individual's physical and psychosocial functions. Pain is also a subjective and personal experience, with a different relevance to the person, as compared to the observer, and, therefore, the patient's own self-reporting of the site, time and description of the type of pain should be used as a clinical indicator.
Historically, the healthcare team members were not directly accountable for providing pain relief, but felt that their responsibility is to control the patient's expression of pain 2, 3 . Recently, the American Pain Society advocated the recognition of pain as the ® fth vital sign to be actively assessed, recorded and attended to 4 .
The patient's complaint of pain in the external genital region has received less attention from the medical community in the way of research, clinical assessment, investigations and treatment. Even at the stage of recognition (e.g. burning vulva syndrome 5 ), this tends to be incarcerated in a subspeciality and the ® ltration to the overall medical and lay community is slow and cumbersome. One of the contributing factors in this process is the fact that pain in the external genitalia (in female and male patients) may be associated with some kind of tissue damage, due to an infection (sexually transmitted or otherwise), mechanical or chemical factors. In the absence of an evidence of this`tissue damage', the clinician may feel that his task has come to an end. Secondly, the increasing incidence of sexually transmitted infections 6 (and the associated pressure on clinicians) is likely to constrict the space available for listening to patients who may present with other problems (e.g. genital pain). The investigation and research into genital pain is hampered by the unfortunate fact that the therapeutic treatment may not appeal to pharmaceutical companies as à revenue generator' and, therefore, the research will receive less priority in ® nancial sponsorship. The new directive of the Department of Health in supporting`research and development' 7,8 may provide a new avenue for an unbiased support and sponsorship for the scienti® c study in this ® eld.
Dysaesthetic vulvodynia has received acknowledgement by the medical community and we propose the recognition of the equivalent condition in the male counterpart: dysaesthetic peno/scroto dynia 9 . Thirdly,`testicular pain of unknown aetiology' would come under this group of conditions, where further understanding is essential and overdue. Resorting to orchidectomy as a line of treatment in patients with testicular pain 10 is an indication of the historical impotence of the medical profession in dealing with pain.
I wish to invite clinicians, with particular interest in the management of patients with genital pain, to communicate their clinical experience, as a step towards pooling expertise and developing aǹ interest group' for the study of`genital pain of unknown aetiology'.
